


WHAT IS CLAIMED IS:

1. A compound of formula (I):



or a pharmaceutically acceptable salt thereof wherein:

W is hydrogen, halogen, cyano, alkyl, alkynyl, cycloalkyl, heterocyclic, aryl, or heteroaryl;

10 R^1 is alkyl, alkynyl, cycloalkyl, heterocyclic, aralkyl, heteroaryl or heteroarylalkyl;

R^2 is SO_2R^3 , $SO_2NR^4R^5$, $C(=O)NR^6R^7$, or $C(=O)R^8$;

X is NR^9R^{10} or $CR^{11}R^{12}R^{13}$;

R^3 is alkyl, alkynyl, cycloalkyl, heterocyclic, aryl or heteroaryl;

R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} and R^{14} are each, independently, hydrogen, alkyl, alkynyl,

15 cycloalkyl, heterocyclic, acyl, aryl, heteroaryl or heteroarylalkyl, wherein

optionally R^4 and R^5 together, R^6 and R^7 together, or R^9 and R^{10} together form a heterocycle incorporating the nitrogen atom;

R^{11} , R^{12} and R^{13} are independently, hydrogen, alkyl, cycloalkyl, heterocyclic, aryl,

heteroaryl or OR^{14} , wherein R^{11} and R^{12} together optionally form a cycloalkyl

20 attached in a spiro fashion, or a heterocylcoalkyl attached in a spiro fashion, or a carbonyl group ($C=O$).

2. The compound according to Claim 1 wherein W is CN and R^1 is arylalkyl or heteroaryl.

25

3. The compound according to claim 1 wherein R^1 is a benzyl or thiophenyl.

4. The compound according to Claim 1 wherein X is $-NR^9R^{10}$ and R^9 is H, alkyl, aralkyl or acyl and R^{10} is heteroaryl or heteroarylalkyl.
5. The compound according to Claim 4 wherein R^9 is H, methyl, benzyl or -C(O)Me.
6. The compound according to Claim 4 wherein R^{10} is imidazolyl.
7. The compound according to Claim 1 wherein $X = CR^{11}CR^{12}R^{13}$ and $R^{11} = H$ or OH; $R^{12} = -OH, -OMe, =O$, or substituted phenyl; and $R^{13} =$ substituted imidazolyl.
8. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
9. The pharmaceutical composition according to Claim 8 further comprising at least one additional anticancer agent.
10. A compound according to Claim 1 selected from the group consisting of:
N-Benzyl-N-[6-cyano-8-(3H-imidazol-4-ylamino)-chroman-3-yl]-methanesulfonamide;
N-[3-(Benzyl methanesulfonylamino)-6-cyanochroman-8-yl]-N-(3H-imidazol-4-yl)acetamide;
N-Benzyl-N-{6-cyano-8-[(3H-imidazol-4-yl)-methyl-amino]-chroman-3-yl}-methanesulfonamide;
N-Benzyl-N-{8-[benzyl-(3H-imidazol-4-yl)-amino]-6-cyano-chroman-3-yl}-methanesulfonamide;
N-Benzyl-N-{6-cyano-8-[hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-chroman-3-yl}-methanesulfonamide;
N-Benzyl-N-{6-cyano-8-[methoxy-(3-methyl-3H-imidazol-4-yl)-methyl]-chroman-3-yl}-methanesulfonamide;

LD0329 NP

N-Benzyl-N-[6-cyano-8-(3-methyl-3H-imidazole-4-carbonyl)-chroman-3-yl]-methanesulfonamide;

N-Benzyl-N-{8-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-6-cyano-chroman-3-yl}-methanesulfonamide;

5 N-Benzyl-N-{6-cyano-8-[methyl-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-chroman-3-yl}-methanesulfonamide;

N-Benzyl-N-{6-cyano-8-[methyl-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-chroman-3-yl}-methanesulfonamide

10 N-{6-Cyano-8-[(pyridin-4-ylmethyl)-amino]-chroman-3-yl}-N-thiophen-3-ylmethyl-methanesulfonamide;

N-[6-Cyano-8-(methyl-pyridin-4-ylmethyl-amino)-chroman-3-yl]-N-thiophen-3-ylmethyl-methanesulfonamide;

N-{6-Cyano-8-[(pyridin-3-ylmethyl)-amino]-chroman-3-yl}-N-thiophen-3-ylmethyl-methanesulfonamide;

15 N-[6-Cyano-8-(methyl-pyridin-3-ylmethyl-amino)-chroman-3-yl]-N-thiophen-3-ylmethyl-methanesulfonamide; and

N-{6-Cyano-8-[(3H-imidazol-4-ylmethyl)-amino]-chroman-3-yl}-N-thiophen-3-ylmethyl-methanesulfonamide;

or a pharmaceutically acceptable salt thereof.

20

11. A method of inhibiting farnesyl protein transferase which comprises administering to a mammalian subject in need thereof a compound of formula I in an amount effective to inhibit farnesyl transferase.

25

12. A method of inhibiting tumors in a mammal which comprises administering to a mammalian subject in need thereof an effective tumor inhibiting amount of a compound of Claim 1.

30

13. The method of Claim 12 further comprising administering to said mammal at least one other anticancer agent.

LD0329 NP

14. A method of treating cancer comprising administering to a mammalian subject in need thereof a pharmaceutically effective amount of a compound according to Claim 1.